Cingulate to Present at H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, will present an overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, from 3:00-3:30 p.m. ET in Miami, FL. The presentation will feature insights from CEO Shane J. Schaffer and CMO Matthew Brams, M.D. Interested investors can access the live webcast and later view a replay on Cingulate’s investor website for 90 days. The company focuses on its proprietary Precision Timed Release™ (PTR™) technology, primarily targeting ADHD treatment while exploring other therapeutic areas like anxiety disorders.

KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, and Chief Medical Officer, Matthew Brams, M.D., will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, from 3:00-3:30 p.m. ET, at the Fontainebleau Miami Beach Hotel, Miami, FL.

A live webcast of the presentation may be accessed at: HCW - Cingulate Live Presentation. A replay will be available on the investor section of Cingulate’s website at Cingulate Events & Presentations for 90 days.

About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, such as anxiety disorders.

Cingulate is headquartered in Kansas City, KS. For more information visit Cingulate.com

Investor Relations 
Thomas Dalton
Head of Investor & Public Relations, Cingulate, Inc.
(913) 942-2301
TDalton@cingulate.com

Matt Kreps
Darrow Associates
(214) 597-8200
mkreps@darrowir.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
(201) 723-5805
mweible@elixirhealthpr.com

FAQ

What will Cingulate present at the H.C. Wainwright Global Investment Conference?

Cingulate will present an overview of its company and pipeline at the conference on May 25, 2022.

Who will represent Cingulate at the conference?

CEO Shane J. Schaffer and CMO Matthew Brams, M.D. will present for Cingulate.

How can I watch the Cingulate presentation live?

You can access the live webcast of the presentation on the company's website.

Where is the H.C. Wainwright Global Investment Conference being held?

The conference will take place at the Fontainebleau Miami Beach Hotel, Miami, FL.

How long will the Cingulate presentation replay be available?

The presentation replay will be available for 90 days on Cingulate's investor website.